Alternatives to DrugClaw

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Physics-based molecular simulation with AI for drug discovery and materials design.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

CURE-Bench is an open-source benchmark grading AI therapeutic decision-making and software-engineering reasoning at scale.

Open-source Python framework that assembles causal and mechanistic models from literature and biological databases.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

AI evidence assembly and quantitative modeling for clinical pharmacology — MBMA databases, Project Optimus dose work, exposure-response

Cellbyte is the AI workspace where pharma Pricing & Market Access teams get source-linked HTA and pricing answers in minutes.

Lamin is a lineage-native open data platform and LaminDB library for traceable, multimodal biotech data — query, govern, and version

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

A research-stage AI platform for discovering neurotherapeutics that act on neural circuits across multiple disorders.

Haplotype Labs builds SaaS and community tooling for population genetics, aiming to cut sequencing costs 50–90% and speed polygenic risk modeling.

PicnicAI turns patient health records into clinical research data and real-world evidence.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.